Financial Performance - Net income for the three months ended September 30, 2025, was $71.92 million, representing a 37% increase compared to $52.45 million for the same period in 2024[10]. - The net earnings per common share for the three months ended September 30, 2025, were $0.76, up from $0.56 in the same period of 2024, a growth of 35.7%[10]. - Comprehensive income for the nine months ended September 30, 2025, totaled $260,011 thousand, up from $241,502 thousand in 2024, reflecting an increase of 7.66%[13]. - Noninterest income for the nine months ended September 30, 2025, increased to $192.67 million, up from $153.71 million in the same period of 2024, a growth of 25.4%[10]. - The company reported a total interest expense of $89.77 million for the three months ended September 30, 2025, down from $101.56 million in the same period of 2024, a decrease of 11.6%[10]. Asset and Liability Management - Total assets as of September 30, 2025, were $18.55 billion, a slight decrease from $18.57 billion on December 31, 2024[8]. - Total deposits rose to $14.43 billion as of September 30, 2025, compared to $14.33 billion at the end of 2024, an increase of 0.7%[8]. - The total fair value of held-to-maturity and available-for-sale investment securities as of September 30, 2025, was $3.488 billion, with total unrealized losses of $263.542 million[38]. - The total fair value of investment securities available-for-sale increased to $3,422.6 million as of September 30, 2025, up from $3,183.8 million as of December 31, 2024, reflecting a rise of about 7.5%[199]. - The total liabilities measured at fair value were $299.9 million as of September 30, 2025, down from $397.5 million as of December 31, 2024, representing a decrease of approximately 24.6%[199]. Loan Portfolio - Total loans and leases decreased to $11.71 billion as of September 30, 2025, from $11.76 billion at the end of 2024, a decline of 0.4%[8]. - The total loan portfolio as of September 30, 2025, includes $627,960,000 in construction real estate loans, with $115,620,000 classified as pass[56]. - The total amount of commercial real estate loans classified as pass for 2025 is $146,543,000, down from $189,777,000 in 2024, indicating a decrease of approximately 22.8%[57]. - The total amount of special mention loans for 2025 is $2,214,000, compared to $2,881,000 in 2024, showing a decrease of approximately 23.1%[57]. - The total amount of substandard loans for 2025 is $250,000, down from $2,618,000 in 2024, indicating a decline of about 90.4%[57]. Credit Quality and Losses - The provision for credit losses for loans and leases was $8.61 million for the three months ended September 30, 2025, compared to $9.93 million for the same period in 2024, indicating a reduction of 13.3%[10]. - The provision for credit losses on loans for the nine months ended September 30, 2025, was $27,567 thousand, down from $38,227 thousand in 2024, a reduction of 28%[21]. - Year-to-date gross charge-offs for commercial and industrial loans are $793,000, while lease financing has year-to-date gross charge-offs of $0[56]. - Total nonaccrual loans increased to $75.951 million as of September 30, 2025, compared to $65.973 million as of December 31, 2024, reflecting a growth of approximately 15.5%[68]. - The allowance for credit losses increased to $161.916 million as of September 30, 2025, up from $158.831 million at the end of September 2024, reflecting a growth of 1.4%[94]. Investment Securities - The total fair value of loans held for sale was $21.5 million as of September 30, 2025, with an unpaid principal balance of $19.8 million, indicating a fair value premium of $1.7 million[204]. - The fair value of mortgage-backed securities (residential) had a fair value of $1.292 billion as of September 30, 2025, with unrealized losses of $74.625 million[38]. - The total amount of cash and due from banks at the end of the period was $174,659 thousand as of September 30, 2025, down from $190,618 thousand at the same time in 2024[21]. - The company recorded impairment losses of $3.4 million and $9.7 million for the three and nine months ended September 30, 2025 and 2024, respectively[41]. - The company assessed that no reserves were needed for AFS securities in an unrealized loss position for the periods ended September 30, 2025, or December 31, 2024[42]. Derivative Instruments and Risk Management - The company monitors its derivative credit exposure through normal credit review processes and maintains collateral agreements with counterparties[130]. - The total notional amount of derivatives designated as qualifying hedging instruments was $1 billion, resulting in a gain of $1.0 million and a loss of $619,000[148]. - The total notional amount of derivatives not designated as qualifying hedging instruments was $19.5 billion, with a gain of $301.9 million and a loss of $300.9 million[150]. - First Financial's interest rate risk management strategy includes the use of derivative instruments such as interest rate caps, floors, and swaps[127]. - The company has the option to defer interest payments on acquired subordinated notes for up to 20 consecutive quarters[124]. Tax and Regulatory Matters - For the third quarter of 2025, income tax expense was $18.8 million, resulting in an effective tax rate of 20.7%, compared to $12.4 million and an effective tax rate of 19.2% for the same period in 2024[167]. - First Financial had no unrecognized tax benefits as of September 30, 2025, and December 31, 2024[168]. - Deferred tax assets increased significantly in the third quarter of 2025 due to the new legislation allowing 100% bonus depreciation for assets placed in service after January 19, 2025[169]. - The company recognized an amortization expense of $4.981 million for tax credit investments in the third quarter of 2025, compared to an expense of $4.622 million for the same period in 2024[166]. - First Financial's investments in affordable housing projects and other tax credit investments totaled $205.590 million as of September 30, 2025, with unfunded commitments of $97.049 million[164].

THIRD QUARTER CONSOLIDATED RESULTS SUNCOKE ENERGY, INC. REPORTS THIRD QUARTER 2025 RESULTS LISLE, Ill. (November 4, 2025) - SunCoke Energy, Inc. (NYSE: SXC) today reported results for third quarter 2025 and provided updated guidance for 2025. "Our third quarter Consolidated Adjusted EBITDA of $59.1 million included two months of results from the addition of Phoenix Global. While the Domestic Coke segment continued to be impacted by the unfavorable mix of contract and spot coke sales, our new Industrial Serv ...

Press Release November 3, 2025 Otter Tail Corporation Announces Third Quarter Earnings, Increases Annual Earnings Guidance and Uplifts Long-Term Financial Targets FERGUS FALLS, Minnesota - Otter Tail Corporation (Nasdaq: OTTR) today announced financial results for the quarter ended September 30, 2025. SUMMARY CEO OVERVIEW "We are pleased with our third quarter financial results," said President and CEO Chuck MacFarlane. "Our team members continue to execute well on our growth plan despite dynamic market con ...

Exhibit 99.1 Ryman Hospitality Properties, Inc. Reports Third Quarter 2025 Results NASHVILLE, Tenn. (November 3, 2025) – Ryman Hospitality Properties, Inc. (NYSE: RHP), a leading lodging real estate investment trust ("REIT") specializing in group-oriented, destination hotel assets in urban and resort markets, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights and Recent Developments: Mark Fioravanti, President and Chief Executive Officer of ...

Revenue and Growth - Revenue from the AVISE® CTD product comprised 89% and 91% of total revenue for the nine months ended September 30, 2025 and 2024, respectively [110]. - The number of AVISE CTD tests delivered increased by approximately 16% year-over-year for the three months ended September 30, 2025, and increased sequentially by approximately 2% over the second quarter of 2025 [118]. - Revenue increased by $4.7 million, or 37.9%, for the three months ended September 30, 2025, compared to the same period in 2024, driven by a 16% increase in AVISE CTD tests delivered and ASP expansion to $441 per test [138]. - For the nine months ended September 30, 2025, revenue was $49.9 million, an increase of $7.9 million compared to $42.0 million for the same period in 2024 [149]. - Revenue increased by $8.0 million, or 19.0%, for the nine months ended September 30, 2025, driven by ASP expansion and an 8% increase in AVISE CTD tests delivered [150]. Product Development and Launches - The company expects to launch a new customized array for Lupus Nephritis biomarkers in the fourth quarter of 2025, initially through Pharma collaborations for research use [113]. - The new PAD4 biomarker assays launched in January 2025 have shown 35% sensitivity and 95% specificity for RA, addressing a critical diagnostic gap [115]. - The company has delivered over one million AVISE CTD tests since its launch in 2012 [118]. - The company plans to continue pursuing partnerships with leading pharmaceutical companies and academic research centers to enhance its testing product portfolio [111]. Financial Performance and Expenses - Cost of revenue increased by $1.6 million, or 29.7%, for the three months ended September 30, 2025, primarily due to increases in materials and employee-related expenses [140]. - Gross margin as a percentage of revenue improved to 58.4% for the three months ended September 30, 2025, compared to 55.8% for the same period in 2024, attributed to ASP expansion and better overhead absorption [141]. - Selling, general and administrative expenses rose by $1.3 million, or 12.6%, for the three months ended September 30, 2025, mainly due to increased employee-related expenses [142]. - Research and development expenses increased by $0.2 million, or 16.8%, for the three months ended September 30, 2025, primarily due to higher employee-related costs [144]. - Interest expense increased by $0.8 million for the three months ended September 30, 2025, primarily due to the Perceptive Term Loan Facility [146]. - The net loss for the three months ended September 30, 2025, was $7.1 million, compared to a net loss of $5.0 million for the same period in 2024 [138]. - Cost of revenue rose by $3.0 million, or 17.3%, primarily due to increased materials and employee-related expenses [151]. - Gross margin improved to 59.3% for the nine months ended September 30, 2025, compared to 58.7% in the same period of 2024, attributed to ASP expansion [152]. - Selling, general and administrative expenses increased by $3.0 million, or 9.7%, mainly due to higher employee-related expenses and travel costs [153]. - Research and development expenses grew by $0.8 million, or 20.9%, primarily due to increased employee-related expenses and outside services [155]. - Net loss for the nine months ended September 30, 2025, was $15.3 million, compared to a net loss of $11.4 million in the same period of 2024 [161]. Cash Flow and Financial Position - Cash and cash equivalents as of September 30, 2025, were $35.7 million, with an accumulated deficit of $309.6 million [161]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $24.8 million, primarily from debt issuance and common stock offerings [176]. Accounting and Reporting - The management's discussion and analysis is based on condensed financial statements prepared in accordance with GAAP, with year-end balance sheets derived from audited financial statements [178]. - There have been no significant changes in critical accounting policies and estimates during the nine months ended September 30, 2025, compared to those disclosed in the 2024 Annual Report [179]. - Recent accounting pronouncements are summarized in "Note 2. Summary of Significant Accounting Policies" in the unaudited condensed financial statements included in the Quarterly Report [180].

Product Launch and Approval - Rezdiffra, the first FDA-approved therapy for MASH, was launched in the U.S. in April 2024 and in Germany in September 2025[118][126]. - The European Commission granted conditional marketing authorization for Rezdiffra, valid in all 27 EU member states[124]. - The company received a Notice of Allowance for a new U.S. patent covering Rezdiffra, providing protection until February 2045[130]. - The company received FDA approval for Rezdiffra in March 2024 and EC approval in August 2025, with a tiered single-digit royalty payable to Roche on net sales[180]. Clinical Trials and Outcomes - Approximately 1.5 million patients in the U.S. are diagnosed with MASH, with 525,000 having moderate to advanced fibrosis[121]. - The MAESTRO-NASH trial showed statistically significant improvement in MASH resolution and fibrosis improvement at 52 weeks[119]. - The company expects to report outcomes data from the MAESTRO-NASH OUTCOMES trial in 2027, which could support full FDA approval for Rezdiffra[119]. - MASH patients with moderate to advanced fibrosis have a 10-to-17 times higher risk of liver-related mortality[120]. Financial Performance - Product revenue for Q3 2025 reached $287.3 million, a 362% increase from $62.2 million in Q3 2024, driven by higher demand for Rezdiffra[143][144]. - For the nine months ended September 30, 2025, product revenue was $637.3 million, a 730% increase from $76.8 million in the same period in 2024[150][151]. - Total operating expenses for Q3 2025 were $401.2 million, up 125% from $178.5 million in Q3 2024, with significant increases in research and development and selling, general and administrative expenses[143][150]. - Net loss for Q3 2025 was $114.2 million, compared to a net loss of $107.0 million in Q3 2024, reflecting a 7% increase in losses[143]. Expenses and Investments - Research and development expenses for Q3 2025 totaled $174.0 million, a 153% increase from $68.7 million in Q3 2024, primarily due to a $120.0 million upfront expense under the CSPC License Agreement[146][147]. - Selling, general and administrative expenses for Q3 2025 were $209.1 million, a 94% increase from $107.6 million in Q3 2024, mainly due to increased commercial activities for Rezdiffra[147][155]. - Interest expense for Q3 2025 was $7.5 million, an increase of 103% from $3.7 million in Q3 2024, due to a higher average outstanding principal balance[149]. Financing and Liquidity - The company secured a Financing Agreement for up to $500 million, including a $350 million initial term loan[129]. - The company entered into a senior secured credit facility in July 2025, providing up to $500.0 million to support operations[159]. - The company anticipates continued significant losses until sufficient revenue is generated from Rezdiffra and other products, with future liquidity needs potentially requiring additional capital[160]. - The company is required to maintain a minimum unrestricted cash balance of $100.0 million at all times under the Financing Agreement[168]. Licensing and Agreements - A global license agreement for MGL-2086 was signed with CSPC, involving an upfront payment of $120 million and potential milestone payments of up to $2 billion[128]. - The company entered into a CSPC License Agreement for MGL-2086, paying an upfront fee of $120.0 million and potentially up to $2.0 billion in milestone payments[181]. - As of September 30, 2025, the company had approximately $187.6 million of obligations under agreements related to active pharmaceutical ingredients, expected to be paid through December 2027[182]. Cash Flow and Market Position - As of September 30, 2025, the company had cash and marketable securities totaling $1,114.7 million, up from $931.3 million as of December 31, 2024[159]. - For the nine months ended September 30, 2025, net cash used in operating activities was $56.1 million, a significant improvement from $351.1 million in the same period of 2024[174]. - Net cash provided by investing activities was $4.7 million for the nine months ended September 30, 2025, compared to a net cash outflow of $226.4 million in the corresponding period of 2024[175]. - The company reported net cash provided by financing activities of $247.0 million for the nine months ended September 30, 2025, down from $715.3 million in the same period of 2024[176]. Risk Factors - The company has not entered into any hedging arrangements for foreign currency risk as it expands operations into Europe, exposing it to fluctuations in exchange rates[185]. - The interest rate on the Term Loans is based on a variable rate, with a current effective rate of 9.1% for the $350.0 million borrowed under the Financing Agreement[184].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 1-31993 STERLING INFRASTRUCTURE, INC. (Exact name of registrant as specified in its charter) Delaware 25-1655321 (State or other ju ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Commission File No. 0-25969 URBAN ONE, INC. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such short ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended September 30, 2025 Delaware 52-1166660 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Commission File No. 0-25969 URBAN ONE, INC. (Exact name of registrant as specified in its charter) 1010 Wayne Avenue, 14th Floor Silver Spring, Maryland 20910 (Address of principal executive offices) Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...